Latest news with #RAPT
Business Insider
17-06-2025
- Business
- Business Insider
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ET UBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025 To access the live webcast or subsequent archived recording of the Goldman Sachs fireside chat, please visit the RAPT Therapeutics website at About RAPT Therapeutics, Inc. RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
Yahoo
14-06-2025
- Business
- Yahoo
Rapt Therapeutics announces effective date for 1-for-8 reverse stock split
RAPT Therapeutics (RAPT) announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'RAPT' with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a reverse stock split-adjusted basis on June 17, 2025. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on RAPT: Disclaimer & DisclosureReport an Issue RAPT Therapeutics Announces Development Plans for RPT904 Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity Rapt Therapeutics initiated with a Buy at Clear Street RAPT Therapeutics Faces Nasdaq Delisting Notice Rapt Therapeutics price target lowered to $1 from $2 at UBS Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
06-06-2025
- Business
- Business Insider
Rapt Therapeutics initiated with a Buy at Clear Street
Clear Street initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $3 price target Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
07-03-2025
- Business
- Yahoo
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2025 at 3:40 p.m. ET Barclays 27th Annual Global Healthcare Conference – Fireside chat on Wednesday, March 12, 2025 at 10:30 a.m. ET To access the live webcasts or subsequent archived recordings of the discussions, please visit the RAPT Therapeutics website at About RAPT Therapeutics, Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases. RAPT Investor Contact:Sylvia Wheelerswheeler@ RAPT Media Contact:Aljanae Reynoldsareynolds@ in to access your portfolio
